2 completed, 1 enrolling by invitation, 1 recruiting. 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 1 | Enrolling by invitation 1 |
Follow Joshua Rosenblat: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) Ketamine Hydrochloride, Midazolam Hydrochloride, Dialectical Behavioral Therapy (DBT) - Borderline Personality Disorder (BPD), Treatment-Resistant Major Depressive Disorder | Phase 2 | Recruiting | Joshua Rosenblat | 120 | 2026-07-16 | 2026-07-29 |
| Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression Group integration therapy - Treatment-resistant Depression (TRD) | Not applicable | Enrolling by invitation | Joshua Rosenblat | 65 | 2026-07-01 | 2026-07-30 |
| Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression Ketamine Hydrochloride - Bipolar Disorder, Bipolar Depression | Phase 2 | Completed | Joshua Rosenblat | 41 | 2022-08-11 | 2026-03-05 |
| Ketamine for Treatment-Resistant Bipolar Disorder Ketamine Hydrochloride, Midazolam Hydrochloride - Bipolar Disorder, Bipolar Depression | Phase 2 | Completed | Joshua Rosenblat | 71 | 2022-07-04 | 2026-03-05 |
Bipolar Disorder (3) · Depressive Disorder, Treatment-Resistant (2) · Borderline Personality Disorder (1) · Depressive Disorder, Major (1) · Suicidal Ideation (1)
Canada (4)
Joshua D. Rosenblat, MD, MSc (1)